Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza ...
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...
Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...
Vaxart ( (VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback